The oncolytic virus T-VEC induces cGAS-STING pathway activation through viral DNA release, with the SOLTI-1503 PROMETEO trial investigating its combination with atezolizumab (anti-PD-L1) to achieve residual cancer burden 0/1 in operable HER2-negative breast cancer patients presenting residual disease after neoadjuvant chemotherapy (88). Here, CGAS is linked to breast carcinoma.